SURVODUTIDE — 10mg

PRE-ORDER — PRICE COMING SOON

GLP-1/GLUCAGON DUAL AGONIST · FAT LOSS

Targets both GLP-1 and glucagon receptors simultaneously. GLP-1 agonism reduces appetite and stabilizes blood sugar; glucagon agonism forces the liver to mobilize and burn stored fat (lipolysis). Key research benefits: significant visceral fat reduction, improved insulin sensitivity, lower triglycerides, and metabolic flexibility — the ability to switch between burning fat and glucose efficiently.

Catalog sizes: 10mg

Research Use Only. This product is intended exclusively for in vitro laboratory research use. It is not for human or veterinary use, has not been evaluated by the FDA, and is not intended to diagnose, treat, cure, or prevent any disease or condition.